NCT02477709View on ClinicalTrials.gov

A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

PHASE2CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

August 7, 2015

Study Completion Date

August 21, 2015

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

Gefapixant

Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only

Trial Locations (1)

28207

American Health Research, Charlotte

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02477709 - A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Biotech Hunter | Biotech Hunter